Omnicell (OMCL) Tops Q2 EPS by 29c; Sees FY Bookings as Low End of Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Omnicell Announces Second Quarter 2023 Results
August 1, 2023 4:01 PM EDTTotal GAAP revenues of $299 million
GAAP net income per diluted share of $0.08
Non-GAAP net income per diluted share of $0.57
FORT WORTH, Texas--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leader in transforming the pharmacy care delivery model, today announced results for its second quarter ended June 30, 2023.
Our second quarter results reflect sequential revenue and profit growth, as we exceeded our previously disclosed guidance ranges for total product and service revenues, non-GAAP EBITDA, and non-GAAP earnings per share, said... More
